Saneca Pharmaceuticals has been acquired by AZC Group
Eterus Capital, a.s. has sold Saneca Pharmaceuticals, a.s. to AZC Group.
Saneca is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns a portfolio of cosmetics and generic products.
Based in Slovakia, AZC is an industrial business group operating in over 20 countries.
Founded in 2008, Eterus Capital is an investor targeting small and medium-sized companies with growth potential, that have successfully proved their business concept. The fund only invests in minority positions, while management control always remains in the hands of the original shareholders.
Oaklins’ team in Slovakia acted as the exclusive sell-side advisor in this transaction.
Talk to the deal team
Related deals
Lumiforte partners with Kartesia to propel global growth and innovation
Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.
Learn moreYxion has been acquired by Normec
Normec has acquired Dutch consultancy Yxion from Antea. Through this acquisition, Normec continues its acquisition strategy in Europe, while also looking for expansion opportunities in the United States.
Learn moreAMC Media Group has been acquired by Formedics
AMC Media Group, a healthcare professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician’s Weekly and OncWeekly.
Learn more